Evidence map›Paper›PMID 28840400›Full record

ReviewHeart failure reviews2017

Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.

Vasiliki Petta, Fotis Perlikos, Stelios Loukides, Petros Bakakos, Athanasios Chalkias, Nicoletta Iacovidou, Theodoros Xanthos, Dorothea Tsekoura, Georgios Hillas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Heart failure reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Vasiliki PettaMedical School, Postgraduate Study Program (MSc) "Cardiopulmonary Resuscitation", National and Kapodistrian University of Athens, Athens, Greece. v_petta@hotmail.com.
Fotis PerlikosPulmonary Division, Department of Critical Care, University of Athens Medical School, Evangelismos Hospital, Athens, Greece.
Stelios Loukides2nd Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Attikon University Hospital, Athens, Greece.
Petros Bakakos1st Department of Respiratory Medicine, National and Kapodistrian University of Athens, Medical School, Sotiria University Hospital, Athens, Greece.
Athanasios ChalkiasMedical School, Postgraduate Study Program (MSc) "Cardiopulmonary Resuscitation", National and Kapodistrian University of Athens, Athens, Greece.
Nicoletta IacovidouHellenic Society of Cardiopulmonary Resuscitation, Athens, Greece.
Theodoros XanthosHellenic Society of Cardiopulmonary Resuscitation, Athens, Greece.
Dorothea TsekouraDepartment of Cardiology, National and Kapodistrian University of Athens, Medical School, Aretaieio University Hospital, Athens, Greece.
Georgios HillasPulmonary Division, Department of Critical Care, University of Athens Medical School, Evangelismos Hospital, Athens, Greece.
National and Kapodistrian University of Athens · GRHellenic Cardiological Society · GREvangelismos Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a major health problem worldwide, with co-morbidities contributing to the overall severity and mortality of the disease. The incidence and prevalence of cardiovascular disease among COPD patients are high. Both disorders often co-exist, mainly due to smoking, but they also share common underlying risk factors, such as aging and low-grade systemic inflammation. The therapeutic approach is based on agents, whose pharmacological properties are completely opposed. Beta2-agonists remain the cornerstone of COPD treatment due to their limited cardiac adverse effects. On the other hand, beta-blockers are administered in COPD patients with cardiovascular disease, but despite their proven cardiac benefits, they remain underused. There is still a trend among physicians over underprescription of these drugs in patients with heart failure and COPD due to bronchoconstriction. Therefore, cardioselective beta-blockers are preferred, and recent meta-analyses have shown reduced rates in mortality and exacerbations in COPD patients treated with beta-blockers.

Indexed as

Cardiovascular DiseasesPulmonary Disease, Chronic ObstructiveAdministration, InhalationAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AntagonistsComorbidityDose-Response Relationship, DrugDrug Therapy, CombinationGlobal HealthHumansRisk FactorsSurvival RateAdrenergic beta-2 Receptor AgonistsAdrenergic beta-AntagonistsBeta-agonistsBeta-blockersCardiovascular diseaseCOPD

Identifiers

PMID28840400
OpenAlexW2749417153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.